Scientists are increasingly examining retatrutide, a promising medication from Eli Lilly, as a significant advance in body management. Unlike many previous approaches, retatrutide is a dual -action receptor targeting both GLP-1 and GIP, hormones that affect appetite and glucose balance. Early cl